Literature DB >> 16912536

[A case of partial response in liver metastatic lesion from gastric endocrine cell carcinoma treated with TS-1].

Norihisa Hanada1, Katsuhiko Inoue, Tomofumi Osako, Kazumi Kuriwaki, Shohei Shimajiri, Mizuho Mochinaga.   

Abstract

Endocrine cell carcinoma (ECC) of the stomach is a rare pathological type with a poor outcome. Standard chemotherapy has not yet been established. We experienced a case of partial response in the liver metastasis from the gastric ECC treated with TS-1. The patient was a 68-year-old female. An upper GI series and gastroendoscopy revealed pyrolus stenosis and CT-scan showed liver metastasis. A non-curative total gastrectomy was performed to allow oral intake. Since the histopathological examination revealed that tumor cells were partially positive for chromogranin A on immunohistochemical study, we diagnosed tumor ECC of the stomach. The patient with liver metastasis was treated using TS-1, and CT-scan showed a remarkable decrease (PR) in the metastatic lesion. TS-1 administration can improve the clinical outcome for ECC of the stomach.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912536

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Gastric mixed adenoneuroendocrine carcinoma with thyroid transcription factor-1-positive neuroendocrine component.

Authors:  Emi Yamaguchi; Yoshitoshi Sato; Takafumi Oe; Takeshi Nishi; Makoto Koike; Yasuhito Kitakado; Kenji Takubo
Journal:  Clin J Gastroenterol       Date:  2015-04-01

2.  Advanced gastric neuroendocrine carcinoma with an adenocarcinoma component.

Authors:  Masashi Miguchi; Masahiko Iseki; Kunihiko Shimatani
Journal:  Case Rep Gastroenterol       Date:  2012-01-25

3.  Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report.

Authors:  Keishiro Aoyagi; Junya Kizaki; Taro Isobe; Yoshito Akagi
Journal:  Surg Case Rep       Date:  2015-12-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.